Jon Twining, MD
Rheumatology · Myrtle Beach, SCNPI 1568492346
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,907 of the $14,068 with a category attached, or 84.6%. It is spread thinly across 37 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations.
Across 717 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AbbVie$3K
- Novartis$2K
- Amgen$1K
- GSK$750
- Lilly USA, LLC$686
- plus $3K from 31 others
What the payments were for
- Consulting fees$2,00014%
- Speaking & faculty fees$380%
- Food & beverage$11,90785%
- Education$1231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 95 | $3,375 |
| AbbVie | 195 | $3,259 |
| Novartis | 93 | $1,690 |
| Amgen(2 entities) | 68 | $1,074 |
| GSK | 57 | $750 |
| Lilly USA, LLC | 38 | $686 |
| AstraZeneca(2 entities) | 14 | $301 |
| Regeneron Healthcare Solutions, Inc. | 11 | $297 |
| E.r. Squibb & Sons, L.L.C. | 16 | $285 |
| Mallinckrodt Hospital Products Inc. | 10 | $253 |
| Pfizer | 23 | $241 |
| Mallinckrodt Enterprises LLC | 12 | $241 |
| UCB, Inc. | 11 | $201 |
| Genentech USA, Inc. | 9 | $169 |
| Medexus Pharma, Inc. | 15 | $165 |
| ANI Pharmaceuticals, Inc. | 7 | $150 |
| Sobi, Inc | 7 | $148 |
| Teva Pharmaceuticals USA, Inc. | 6 | $113 |
| Fresenius Kabi USA, LLC | 4 | $110 |
| Radius Health, Inc. | 3 | $54 |
| Bristol Myers Squibb | 3 | $51 |
| Boehringer Ingelheim | 1 | $49 |
| Janssen Scientific Affairs, LLC | 1 | $49 |
| Eisai Inc. | 2 | $44 |
| Argenx US, Inc. | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $38 |
| Acorda Therapeutics, Inc | 2 | $38 |
| Sandoz | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $26 |
| Mylan Institutional Inc. | 1 | $22 |
| Organon | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Harmony Biosciences LLC | 1 | $21 |
| Biogen | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Orthogenrx Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$2,000
- SIMPONI ARIA$2,000
- NUCALA$113
How this compares
$14,068 in reported general payments places this provider in the 70th percentile of 123 rheumatology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 69 | $699,167 |
| Humira(Cf) PenAdalimumab | 31 | $463,578 |
| Humira PenAdalimumab | 27 | $350,713 |
| Humira(Cf)Adalimumab | 17 | $276,752 |
| RinvoqUpadacitinib | 27 | $228,233 |
| HumiraAdalimumab | 20 | $143,124 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $85,565 |
| Xeljanz XrTofacitinib Citrate | 11 | $67,128 |
| OxycontinOxycodone Hcl | 28 | $24,621 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 375 | $13,928 |
| Hydroxychloroquine Sulfate | 265 | $12,544 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 407 | $8,833 |
| MethotrexateMethotrexate Sodium | 250 | $8,270 |
| Xtampza ErOxycodone Myristate | 14 | $8,155 |
| JardianceEmpagliflozin | 12 | $7,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq, Humira, Synthroid | $3,259 | $650,07097 claims |
| Boehringer IngelheimJardiance | $49 | $7,15512 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $15 | $3,37332 claims |
| Hikma Pharmaceuticals USABuprenorphine | $12 | $2,01018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Myrtle Beach
- Douglas ConawayMyrtle Beach$500K
- Gerald LarochelleMyrtle Beach$24K
- Rabih NayfeMyrtle Beach$21K
- Wendy LeeMyrtle Beach$18K
- David LazarMyrtle Beach$16K
- David ChetritMyrtle Beach$8K
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.